NEW HAVEN, Conn., Oct. 08, 2024 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (PRPO) (NASDAQ: PRPO) announces the launch of a new version of its Bloodhound MPN ...

New research unveils a promising monoclonal antibody therapy targeting mutant calreticulin in essential thrombocythemia, aiming to improve patient outcomes.

Multi-hit TP53 mutations are linked to poor survival in both MPN and AML, with median OS ranging from 4.8 to 11.6 months. Factors such as ASCT, pre-transplant therapy response, and concurrent TET2 or ...

Physician-patient communication and shared decision-making approaches in myeloproliferative neoplasm care. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This abstract does not ...

A study reveals that azacitidine, especially in combination with ruxolitinib, improves survival in patients with advanced ...

Results from a retrospective study compared and explored biomarkers associated with outcomes in myelodysplastic syndrome (MDS) with plasma cell neoplasms. MDS is a group of heterogeneous clonal ...

A subset of patients with myeloproliferative neoplasms (MPNs) -- clonal disorders of hematopoietic stem cells that include polycythemia vera and essential thrombocythemia, as well as primary ...

Chronic myeloid leukaemia (CML) is a paradigmatic clonal disorder primarily driven by the BCR-ABL translocation, which produces a constitutively active tyrosine kinase. Traditionally, this genetic ...

BOZEMAN, MONTANA, USA, February 1, 2024 /EINPresswire.com/ -- Alercell, Inc., an innovative leader in molecular diagnostics, has recently unveiled its latest ...